摘要
目的探讨G-CSF联合高三尖杉酯碱和小剂量阿糖胞苷之CHG预激化疗方案治疗难治性急性髓系白血病的临床疗效、不良反应,寻求高效安全、毒副反应小的新型化疗方案。方法应用CHG标准预激化疗方案治疗68例难治性急性髓系白血病(AML),与常规TA化疗方案比较,观察临床疗效、各种不良反应、毒副作用、治疗相关死亡率。结果总缓解率63.2%(完全缓解率44.1%,部分缓解率19.1%),较TA方案缓解率显著增高(P<0.05),无严重内脏出血,粒细胞缺乏44.1%,平均持续时间4.5d,无重症感染、严重消化道反应和心、肝、肾功能损害。结论CHG预激化疗方案治疗难治性急性髓系白血病疗效显著,无严重毒副反应,严重治疗相关死亡率均较低,是高效安全的新型化疗方案。
Objective To explore the clinical efficacy, adverse reactions of G-CSF joint Homoharringtnniue and lowdose Ara-C CHG preexcitation of chemotherapy in the treatment of refractory acute myeloid leukemia,and to search the efficient,safe,small toxicity new method of chemotherapy. Methods 68 cases of refractory acute myeloid leukemia（AML）was treated with CHG standard chemotherapy and clinical efficacy,adverse reactions,side effects,treatment-related mortality were compared with conventional chemotherapy with TA. Results The overall remission rate was 63.2%（complete remission rate of 44.1%,partial remission rate of 19.1%）.h had significantly higher remission rate than TA chemotherapy （P〈0.05）with no severe visceral hemorrhage, agranulocytosis 44.1% ,with an average duration of 4.5 days,no severe infection,severe gastrointestinal reactions and heart,liver and renal dysfunction. Conclusion It has significant efficacy of CHG preexcitation chemotherapy in the treatment of refractory acute myeloid leukemia,without serious adverse reactions and low serious treatment-related mortality rates.It is a new type of efficient and safe chemotherapy.
出处
《中国现代医药杂志》
2009年第3期22-24,共3页
Modern Medicine Journal of China
关键词
预激化疗
G—CSF
急性髓系白血病
难治复发
疗效
Preexcitation of chemotherapy G-CSF Aate myeloid leukemia Refraetory relapse Efficacy
